• Bafna Pharmaceuticals board meeting scheduled for May 29, 2026 to approve audited Q4 and FY26 results.
• Trading window closed from April 1 to May 31, 2026 for designated persons due to results consideration.
• Disclosure made under SEBI LODR Regulation 29 for mandatory board meeting intimation.